S. Chabaud(1,2), P. Girardd(1,2), P. Nony(1,2), JP. Boissel(1,2) and THERMOS group(3) Use of a Therapeutic Model for Simulating Phase III Clinical Trials of a New Bradycardic Agent
|
A.C. Davison Bootstrap Methods
|
Stephen Duffull(1), Leon Aarons(1) and the THERMOS group(2). Development of a Linked Pharmacokinetic and Pharmacodynamic Simulation Model for Ivabradine in Healthy Volunteers
|
Gilles Freyer(1), Brigitte Tranchand(2), Blandine Ligneau(1), Claude Ardiet(2), Pierre-Jean Souquet(3), Isabelle Court-Fortune(3), Robert Riou(3), Paul Rebattu(4), Véronique Trillet-Lenoir(1,6), Jean-Pierre Boissel(5,6), Pascal Girard(5,6). Population Pharmacokinetic Parameters of Doxorubicin, Ifosamide and Etoposide in Small Cell Lung Cancer Patients
|
R. Gomeni(1), I. Cognet(1) and F. Servin(2) Population Analysis (NONMEM) using a Concentration-to-Event Approach to Evaluate the Propofol Anaesthesia Induction Strategy using a Target Controlled Infusion (TCI) System: Diprifusor TCI
|
Gordon Graham, Leon Aarons Optimal Design for Categorical Data
|
R Jelliffe(1), A Schumitzky(1), D Bayard(1), M Van Guilder(1), X Wang(1), M Milman(1), S Leonov(1), R Leary(2), P Maire(3), X Barbaut(3), and S Lecoq(3) Population PK/PD Modeling and Optimal Drug Dosage
|
E. Niclas Jonsson1,2 and Lewis B. Sheiner2 Quantifying Non-Standard Evidence for Drug Approval
|
Byron Jones Constructing optimal designs for fitting pharmacokinetic models
|
MO Karlsson, RC Schoemaker, B Kemp, A Cohen, J van Gerven, M Danhof A Pharmacodynamic Markov Mixed Effect Model for Temazepams Effect on Sleep
|
Peter A. Milligan1, Scott F. Marshall1, Mats O. Karlsson2 A Population Pharmacokinetic and Pharmacodynamic Analysis of Sildenafil Phase III Data
|
Per Olsson Gisleskog1 & Mats O Karlsson2 The Use of Priors in NONMEM Population Analysis
|
M. Tod Robust optimal design for hyperparameter estimation
|
Janet R. Wade(1) and Mats O. Karlsson(2) Combining PK and PD data during population PK/PD analysis
|
Andanson M.(1,2), Girard P.(1) , Chabaud S.(1) , Charpiat B.(2), Fourcade N.(3), Ducerf C.(4) Population Pharmacokinetic Study of Tacrolimus in Liver Transplanted Patients
|
C Chauvet (1), S Rochegude(1), N Bleyzac(1,2), P Maire(2), G Putet(3), G Aulagner(1). Bayesian Monitoring of Vancomycin Concentrations in Newborns: Choice of the Optimal Covariate of Elimination
|
E Chatelut, L Rostaing, N Grégoire, J-L Payen, A Pujol, J Izopet, G Houin, and P Canal A Pharmacokinetic Model for Alpha Interferon Administered Subcutaneously
|
S. Corvaisier1, B. Charpiat 1, G. Leboucher 1, M. Wallon 2, M. Al Kurdi 2, F. Peyron 2, C. Mounier3, and J.F. Chaulet 3. Population pharmacokinetic in ambulatory new-borns treated with long elimination half-time drugs for chronic asymptomatic infectious disease. Which blood sampling design and data collection process to adopt ?
|
S. Corvaisier (1), N. Bleyzac (2), P. Maire (1,3). Influence of Errors in Data Collection on Estimated Population Pharmacokinetic Parameter Values and Proposed a Priori Dosage Regimen
|
V. Cosson, R. Jochemsen, M. Dubar, J.M. Delbos, H. Merdjan. Simulation, a Tool for Designing the Suitable Formulation: Example of S 18326
|
Marie Cullberg1), Ulf Eriksson1), Mats Karlsson2) Population Modelling of the Effect of Inogatran on ex vivo Coagulation Time (APTT) in Healthy Males and Patients
|
Dinesh P. de Alwis, Iñaki F. Troconiz*, Christiane Tillmann and Hans G. Schaefer Population PK/PD Modelling of Moxonidine in Hypertensive Patients using Manual and 24h-Ambulatory Blood Pressure Data
|
Dinesh de Alwis and Leon Aarons Comparison of Model Dependent and Independent Population Pharmacokinetic Analyses
|
C. Dubruc, S. Chaufour, P. Rosenzweig, J.P. Thenot and F. Mentré* Population Pharmacokinetic Analysis of Mizolastine in Children 6 to 12 Years Old using NONMEM
|
T. Funaki Enterohepatic circulation model for population pharmacokinetic analysis
|
MJ García1, D Santos Buelga1, A Blázquez2, A Torregrosa2, J Manzanares2, P Urruzuno2, E Medina2, and C Manzanares2 Population Pharmacokinetics of Tacrolimus in Pediatric Liver Transplant Patients under Rescue Therapy
|
R. Gieschke, B. Reigner, J.-L. Steimer Capecitabine Population Pharmacokinetics of Combined Sparse Data from Phase II Breast Cancer Patients and Extensive Data from a Bioequivalence Study
|
P. Girard, F. Varret A Population Model for Compliance and Drop-out Model for Once a Day Regimen in Depressed Patients
|
Georg Hempel1,2, Christiane Eickhoff3, Charlotte Kloft3, Ulrich Jaehde4 Comparison of Three Methods to Analyse the Population Pharmacokinetics of High-Dose Carboplatin in Patients with Testicular Carcinoma
|
Fredrik Jonsson1, Gunnar Johanson1, 2, and Frédéric Y Bois3 Applying a Population Model to Physiologically Based Modeling of Human Exposure to Dichloromethane Vapor using Markov Chain Monte Carlo Simulations
|
S. Jönsson and M.O. Karlsson A Rational Approach for Establishing Dosing Algorithms in Renal Impairment
|
Mats. O. Karlsson, Sima Sadray and E.Niclas Jonsson Likelihood-based Diagnostics for Influential Individuals in Non-Linear Mixed Effects Model Selection
|
Lanao JM, Atencio DR, Martín-Suárez A, Méndez ME*, López FG, Zarzuelo A Study of the Digoxin-Acenocoumarol Interaction in Patients using Population Pharmacokinetics
|
Llopis MC(1,3), Pérez-Ruixo JJ(1), Medina C(1), Azagra P(2), Casabó VG(2); Jiménez NV(1,3). Population Pharmacokinetics of High Dose of Cyclophosphamide in High Risk Breast Cancer Patients
|
Harry Mager PK/PD Modelling: The Problem Of Chance Correlations In Population Pharmacokinetics
|
France Mentré1, John Kovarik2 , Christophe Gerbeau2 Constructing a Prediction Interval for Time to Reach a Threshold Concentration Based on a Population Pharmacokinetic Analysis: an Application to Basiliximab in Renal Transplantation
|
Y.Merlé1, J.M. Tré Luyer2 and G.Pons2 Population Analysis of Pediatric Pharmacokinetic Data of Netilmicin Accounting for Dilution Errors Before Infusion
|
Stéphane Mouly(1), Saik Urien(2), Jean-Paul Tillement(2), Jean-François Bergmann(1), and Charles Caulin(1) Population Pharmacokinetics of Oral Gancyclovir In 42 HIV-Infected Patients With and Without Diarrhea
|
O. Petricoul, E. Fuseau. Meta-Analysis of the Exposure/Efficacy Relationship for Sumatriptan Nasal Spray
|
B. Vrijens and E. Goetghebeur The impact of Compliance in Population Pharmacokinetic (PK)/ Pharmacodynamic (PD) Modeling
|
Willi Weber, Lutz Harnisch Application of Dose Response Modeling to anti-Rheumatic Leflunomide Therapy
|
Ulrika Wählby, E. Niclas Jonsson and Mats O. Karlsson Determination of Inclusion Frequency of False Covariate Relationships in Population Modelling
|
G. Würthwein(1), S. Krümpelmann(2), J. Boos(1) Population Pharmacokinetic Approach to Compare Oral and IV Administration of Etoposide
|
A. Mallet Non-parametric methods for continuous and binary variables in population PK/PD.
|
M. Looby Characterisation of dose response in early drug development: A case study
|
Barry Jones Pharmacogenetics
|